A pilot study of rice bran arabinoxylan compound (RBAC) supplementation on the nutritional status of participants with colorectal cancer.

None listed

Brief description of the study purpose This research aims to investigate the potential of rice bran arabinoxylan compound (RBAC) as an immunonutrition supplement to improve the nutritional status and quality of life (QoL) of colorectal cancer (CRC) patients, with the goal of preventing malnutrition and complementing primary oncological treatments of surgery, chemotherapy and radiotherapy. Who is it for? You may be eligible for this study if you are male or female age 18 years or older, with histologically confirmed diagnosis of colorectal adenocarcinoma at stage II or above and currently undergoing chemotherapy. Study details Participants who meet the eligibility criteria will be prospectively randomised to receive either RBAC or a placebo. Participants will be instructed to take their allocated intervention once daily in sachet form for 24 weeks. During and at the completion of the intervention period, participants will undergo blood testing to assess nutritional status, metabolic parameters, and inflammatory markers. Stool samples will also be collected to evaluate the gut microbiome. Participants will be asked to complete both self-reported and clinician-administered assessments relating to malnutrition, cachexia, quality of life, and fatigue throughout the study.

No related papers found yet.